Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC


Herbst R. S., Giaccone G., de Marinis F., Reinmuth N., Vergnenegre A., Barrios C. H., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.383, sa.14, ss.1328-1339, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 383 Sayı: 14
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1056/nejmoa1917346
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Sayfa Sayıları: ss.1328-1339
  • İstanbul Üniversitesi Adresli: Hayır

Özet

BackgroundThe efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.